In the global intention-to-treat population, Pola-R-CHP showed significant progression-free survival benefit over R-CHOP ...
Diffuse large B cell lymphoma (DLBCL) is a prevalent subtype of non-Hodgkins lymphoma and can occasionally present as a rare and aggressive testicular variant. This case presents a middle-aged male ...
New findings support a shift away from the long-standing 30-Gy standard established before rituximab and PET response assessment.
CAR2119’s single-infusion approach offers cost and compliance advantages, though its competitors maintain strong commercial ...
In this video, Tycel Phillips, MD, discusses initial results of a phase 1b clinical trial focused on treating diffuse large B ...
Zacks Investment Research on MSN
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio?
Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 ...
Researchers assessed the safety and efficacy of combining glofitamab with R-CHOP or Pola-R-CHP among patients with high-risk LBCL aged 65 years or younger.
Jeremy S Abramson and colleagues reported that glofitamab plus gemcitabine and oxaliplatin (GemOx) significantly improved overall survival (OS) in transplant-ineligible patients with relapsed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback